These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23834158)

  • 101. Blood component processing technique and plasma quality.
    Suontaka AM; Bremme K; Akerblom O; Blombäck M
    Infusionsther Transfusionsmed; 1992 Jun; 19(3):110-4. PubMed ID: 1498550
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 103. Minimal impact of anticoagulant on in vitro whole blood quality throughout a 35-day cold-storage regardless of leukoreduction timing.
    Schubert P; Culibrk B; Bhakta V; Closas T; Sheffield WP; Devine DV; McTaggart K
    Transfusion; 2022 Aug; 62 Suppl 1():S98-S104. PubMed ID: 35748674
    [TBL] [Abstract][Full Text] [Related]  

  • 104. [Role of quality control for improvement of blood components in the Regional Blood Centre of Ouagadougou in Burkina Faso, 2014].
    Nebie K; Sawadogo S; Kafando E; Bationo EM; Dahourou H; Ouattara S; Kienou K; Nana S; Kaba L; Fretz C; Murphy EL
    Transfus Clin Biol; 2017 Nov; 24(4):431-439. PubMed ID: 28583468
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Blood collection and the labile blood components: what should the regulators ask for?
    Maniatis A; Adamides E
    Vox Sang; 1998; 74 Suppl 2():523-5. PubMed ID: 9704493
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Developing effective working partnership with manufacturers.
    Pujol-Reyz A
    Transfus Sci; 1998 Dec; 19(4):375-6. PubMed ID: 10351161
    [No Abstract]   [Full Text] [Related]  

  • 107. Process improvement by eliminating mixing of whole blood units after an overnight hold prior to component production using the buffy coat method.
    Mastronardi C; Schubert P; Levin E; Bhakta V; Yi QL; Hansen A; Stewart T; Jenkins C; Lefresne W; Sheffield W; Acker JP
    J Blood Transfus; 2013; 2013():154838. PubMed ID: 24066260
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A study on the correlation between hemoglobin concentration and the storage quality of suspended red blood cells prepared from the whole blood of Tibetan male residents.
    Zhong R; Wu X; Liu Z; He Z; Zhang X; Liu J; Cao Y; Wang H
    Front Med (Lausanne); 2022; 9():1062778. PubMed ID: 36743680
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Impact of technical and assay variation on reporting of hemolysis in stored red blood cell products.
    Almizraq RJ; Yi QL; Acker JP;
    Clin Chim Acta; 2017 May; 468():90-97. PubMed ID: 28228350
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Systematic RBC leucodepletion in France: where are we after six months?
    Masse M
    Transfus Sci; 2000; 22(1-2):57-9. PubMed ID: 10771383
    [No Abstract]   [Full Text] [Related]  

  • 111. Evaluating blood product quality post expiry to mitigate blood shortages during the COVID-19 pandemic in Canada.
    Turner TR; Olafson C; Mykhailova O; Xu A; Acker JP
    Transfusion; 2020 Dec; 60(12):3072-3074. PubMed ID: 33009667
    [No Abstract]   [Full Text] [Related]  

  • 112. Sickle cell trait results in a high leukoreduction quality control failure rate for whole blood donations.
    Gehrie EA; Petran L; Young PP
    Transfusion; 2022 Sep; 62(9):1727-1730. PubMed ID: 35841199
    [TBL] [Abstract][Full Text] [Related]  

  • 113. The effect of holding times of whole blood and its components during processing on in vitro and in vivo quality.
    van der Meer PF; de Korte D
    Transfus Med Rev; 2015 Jan; 29(1):24-34. PubMed ID: 25432073
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Red blood cells, plasma, and other new apheresis-derived blood products: improving product quality and donor utilization.
    Smith JW; Gilcher RO
    Transfus Med Rev; 1999 Apr; 13(2):118-23. PubMed ID: 10218235
    [No Abstract]   [Full Text] [Related]  

  • 115. [Innovative technology and blood safety].
    Begue S; Morel P; Djoudi R
    Transfus Clin Biol; 2016 Nov; 23(4):245-252. PubMed ID: 27616610
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The quality of stored umbilical cord and adult-donated whole blood in Mombasa, Kenya.
    Hassall O; Maitland K; Fegan G; Thitiri J; Pole L; Mwakesi R; Denje D; Wambua K; Mandaliya K; Bates I
    Transfusion; 2010 Mar; 50(3):611-6. PubMed ID: 19912583
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Automation/computerization in blood processing.
    Pietersz RN
    Transfus Sci; 1995 Sep; 16(3):235-41. PubMed ID: 10159878
    [No Abstract]   [Full Text] [Related]  

  • 118. Comparison of blood component preparation systems based on buffy coat removal: component specifications, efficiency, and process costs.
    van Delden CJ; de Wit HJ; Sibinga CT
    Transfusion; 1998 Sep; 38(9):860-6. PubMed ID: 9738627
    [No Abstract]   [Full Text] [Related]  

  • 119. An insight to the internal quality control of blood components separated using the latest whole blood collection and processing systems: Experience from a tertiary care hospital blood transfusion service in Eastern India.
    Das SS; Biswas RN; Sardar TP; Safi M
    Asian J Transfus Sci; 2022; 16(2):194-200. PubMed ID: 36687542
    [TBL] [Abstract][Full Text] [Related]  

  • 120. U.S. licensed blood banks. Evaluation of whole blood and its components.
    Lacerte JM; Kane VM; Cohen P
    Transfusion; 1972; 12(5):339-43. PubMed ID: 5072586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.